Trial Profile

A Long-term Extension Study to Evaluate the Safety and Tolerability of TAK-861 in Participants With Selected Central Hypersomnia Conditions

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 13 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Oveporexton (Primary)
Indications Cataplexy; Narcolepsy
Focus Adverse reactions
Sponsors Takeda; Takeda Development Center Americas

Most Recent Events

25 Sep 2024 Planned End Date changed from 30 Jun 2028 to 28 Feb 2028.
25 Sep 2024 Planned primary completion date changed from 30 Jun 2028 to 28 Feb 2028.
19 Sep 2024 According to a Takeda media release, additional data from the Phase 2b trials will be presented at the at Sleep Europe 2024, the 27th Congress of the European Sleep Research Society (ESRS), being held September 24-27, 2024 in Seville, Spain.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com